// App-Quantinova.ai

1339 : Effects of INCB052793, a selective JAK1 inhibitor, in combination with standard of care agents in human multiple myeloma (MM) cell lines and xenograft models

Researchers

Presenter

  • Eric Sanchez

Principal Investigators

  • Mingjie Li

  • Cathy Wang

  • Puja Mehta

  • George Tang

  • Haiming Chen

  • James R. Berenson

Medical Centers

  • Institute for Myeloma & Bone Cancer Research, Beverly Hills, CA.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Immunoglobulin G

  • Interleukin 6

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bendamustine

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • carfilzomib Intravenous

  • INCB052793

  • Melphalan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved